Key result
DDX3 acts as a double-edged sword in the host immune response and viral replication, serving as a promising target for anticancer and antiviral treatments.
Why the study?
Increasing evidence suggests DDX3 is a promising, viable target for anticancer and antiviral treatments, playing a dual role in viral replication and host immune response.
DDX3 is a promising target for antiviral and anticancer therapies due to its dual role in host immune response and viral replication.
Answers are grounded in this paper and cite their sources.
DDX3 modulation merits cautious preclinical study; leaves open context-specific targeting strategies for cancer and viral disease.
DDX3 is a cellular ATP-dependent RNA helicase involved in different aspects of RNA metabolism ranging from transcription to translation and therefore, DDX3 participates in the regulation of key cellular processes including cell cycle progression, apoptosis, cancer and the antiviral immune response leading to type-I interferon production. DDX3 has also been described as an essential cellular factor for the replication of different viruses, including important human threats such HIV-1 or HCV, and different small molecules targeting DDX3 activity have been developed. Indeed, increasing evidence suggests that DDX3 can be considered not only a promising but also a viable target for anticancer and antiviral treatments. In this review, we summarize distinct functional aspects of DDX3 focusing on its participation as a double-edged sword in the host immune response and in the replication cycle of different viruses.
No takes yet. Share an insight, caveat, or question.
Hernández‐Díaz et al. (2021) conducted a review in Viral infection and cancer. DDX3 was evaluated. DDX3 acts as a double-edged sword in the host immune response and viral replication, serving as a promising target for anticancer and antiviral treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: